Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical Limited has announced the approval for marketing of its newly developed medical imaging product, ‘Gadoteridol Injection’, in China. This MRI contrast agent, known as Daxian, is expected to meet the high demand in the Chinese medical imaging market, which exceeds RMB 10 billion. The product joins the company’s portfolio of diagnostic imaging agents, promising to enhance clinical MRI options and benefit a larger patient base.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
